International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Getting to Know IPC’s Board Member Bruce Strober: What Inspired Me to Specialize in Psoriasis

Bruce Strober, MD, PhD

Central Connecticut Dermatology

Cromwell, Connecticut, United States

Vice President/President-Elect

Bio
  • He currently is the Vice President and President-Elect on the Board of the International Psoriasis Council.
  • He is a Clinical Professor of Dermatology at Yale University School of Medicine, the Scientific Co-Director of the CorEvitas Psoriasis Registry, and the Editor in Chief of the Journal of Psoriasis and Psoriatic Arthritis.
  • Strober earned his medical and doctorate degrees from Columbia University in New York, New York. He subsequently completed his residency in dermatology at the Department of Dermatology at New York University School of Medicine in New York, New York. He is board-certified by the American Board of Dermatology and a Fellow of the American Academy of Dermatology.
  • Strober’s research interests include the study of old and new therapeutics for inflammatory skin disease, specifically interventions that help patients with difficult-to-treat psoriasis, atopic dermatitis, and hidradenitis suppurativa. Additional research interests include elucidating novel features of inflammatory skin disease not previously uncovered and assisting in clarifying the pathophysiology of inflammatory skin disease. He has served as principal investigator or sub-investigator for numerous multicenter clinical studies.
  • Before co-founding Central Connecticut Dermatology, Dr. Strober was Professor and Chair in the Department of Dermatology, University of Connecticut School of Medicine in Farmington, Connecticut.

Understanding psoriasis isn’t just a profession for Dr. Bruce Strober; it’s a lifelong commitment. As the Vice President and President-Elect of the International Psoriasis Council (IPC), Dr. Strober has dedicated his career to unraveling the complexities of this challenging skin condition.

Dr. Strober’s journey began during his time at Columbia University, where he earned his medical and doctorate degrees, and his fascination with dermatology took root. It was during his residency at New York University School of Medicine (NYU) that he chose to specialize in psoriasis when he first used the biologic therapy etanercept and saw how it impressively changed the lives of people who suffered from psoriasis and psoriatic arthritis. Subsequently, he was a principal investigator in nearly every study investigating new medicines for psoriasis and relished the revolution these medicines were bringing to medical dermatology. Over two decades, psoriasis went from a curse to a highly treatable condition.

"Life mirrors golf: Your most difficult shot/step is the next one."

— Bruce Strober, MD, PhD, IPC Vice President/President-Elect

With his role as the Scientific Co-Director of the CorEvitas Psoriasis Registry and Editor-in-Chief of the Journal of Psoriasis and Psoriatic Arthritis, Dr. Strober has been at the forefront of groundbreaking research. His contributions, including over 220 published book chapters and articles in leading journals such as JAMA Dermatology and the New England Journal of Medicine, have solidified his position as a thought leader in the field.

Beyond his academic achievements, Dr. Strober co-founded Central Connecticut Dermatology, leaving a legacy that continues to impact patients’ lives.

For Dr. Strober, the heart of his work lies in improving the quality of life for those affected by psoriasis. “Every patient deserves a chance at a better life, and it’s our duty as dermatologists to make that a reality,” he emphasizes.

His long-standing commitment to the IPC, dating back to 2005, speaks volumes about his dedication to the cause. Notably, his leadership in the IPC’s recent statement on the recategorization of psoriasis severity has reshaped how the medical community approaches the treatment of psoriasis with systemic and biologic therapies.

Dr. Bruce Strober’s journey isn’t just about professional success; it’s a testament to the power of passion and perseverance in making a tangible difference in the lives of those affected by psoriasis.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Focus on Psoriasis: A Report from the 2024 American Academy of Dermatology (AAD) Annual Meeting

Psoriasis in Older Patients: Epidemiology, Clinical Features, and Treatment Discussion

SPEVIGO® Receives Approval for Expanded Indications in China and the United States

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.